The Wayback Machine - https://web.archive.org/web/20101231174831/http://www.the-scientist.com/supplement/2008-7-1/
Welcome to The Scientist's special supplement. Scroll down for the table of contents.
By Stephen Pincock and Richard Gallagher

POLICY
SECTION I
How Ireland grew from life science irrelevance to global research hub in 50 years.
By Sean Duke
A competitive research base will deliver a robust and flexible economy.
By Helena Acheson
Famously private, and equally generous, Chuck Feeney helped transform Irish academic research.
By Cormac Sheridan
Decades of emigration left scars on the Irish psyche, but Ireland is reaping the benefits as its diaspora returns.
By Karlin Lillington
Positioning Ireland as a location for life sciences is a welcome challenge for the head of IDA Ireland.
By Cormac Sheridan
Enterprise Ireland's unique public-private approach to getting research into business.
By Paul Roben
The turn to science in Emerald Isle has happened without much public support.
By Brian Trench
Ireland's chief scientific advisor began as a classics scholar, but was soon won over to animal genetics.
By Cormac Sheridan
INDUSTRY
SECTION II
Two new Dublin institutes are helping position Ireland as a world force in bioprocessing.
By Mary Sweetman
The pharmaceutical industry is thriving in Ireland.
By Pat Duffy and Matt Corcoran
Old-world courtesy helped him rise from untrained bank clerk to the driver of major pharma projects.
By Cormac Sheridan
Former personnel are spreading the 'Elan testosterone' throughout Irish life sciences.
By Cormac Sheridan
Irish companies provide multinational pharmaceutical companies with a host of services.
By Anna Nolan
Approaching 80, the founder of Galen and Almac attributes his success to persistance and a special kind of stupidity.
By Karlin Lillington
Nourished by research funding and optimism, new biotechnology firms are sprouting across the country.
Opsona Therapeutics: Taking a new approach to Toll-like receptors
Merrion Pharmaceuticals: Delivering on expectations
Biotrin A biomarker stalwart
Celtic Catalysts: A focus on chiral drugs
Alimentary Health: Developing probiotics for clinical use
AGI Therapeutics: Repurposing old drugs for gastrointestinal indications
IdentiGEN: Old bones, new technology
By Cormac Sheridan
This Australian-born, Ireland-based serial entrepreneur is always on the lookout for biotech cherries ripe for the picking.
By Karlin Lillington
How the closure of a computer manufacturing plant gave rise to Galway's thriving medical devices industry.
By Cormac Sheridan
RESEARCH
SECTION III
Bench-to-bedside research is profiting from a collaborative spirit in Northern Ireland and the Republic of Ireland.
By Mary Sweetman
Excellent science and researchers are what's needed for Ireland's future High-tech economy.
By Frank Gannon
The "pharmabiotic" researcher from University College Cork has his mother to thank for his career choice.
By Karlin Lillington
Thanks to the growth in government funding, Irish universities can now cooperate, not just compete.
By Anna Nolan
Research in Ireland
Understanding Alzheimer's Disease: Harald Hampel and his team zero in on the disease's biomarkers.
A Matter of Breeding: Emmeline Hill is taking her family's horse-breeding history into the genomic era.
Gut Instincts: Patrick Johnston's team is using transcriptome mapping to help choose treatments for colorectal cancer.
Combination Therapy: Galway's Remedi center brings together stem cells and gene therapy to tissue repair.
Drawn to Death: Apoptosis has fascinated Trinity College Dublin's Seamus Martin since his PhD 20 years ago.
Sweet Spot: Diabetes researchers at the University of Ulster may have hit a winner with a hormone dubbed GIP.
By Mary Mulvihill
Three top immunologists moved back to Ireland in the 1990s and have been attracting great researchers ever since.
By Karlin Lillington
Will tight education funding hinder Ireland's efforts to build a knowledge economy?
By Sean Duke